This entry was posted on Monday, March 30th, 2009 at 4:56 am and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
CMO – MODERN MIRACLE AGAINST ARTHRITIS? A REVOLUTIONARY DISCOVERY – BURIED FOR 25 YEARS
Back in the early 1970s a researcher in the employ of the U.S. Government National Institutes of Health (NIH) made a discovery. In a certain strain of laboratory rats he found a substance that not only made animals immune to getting arthritis, but also cured afflicted animals. The substance, originally extracted from ground up Swiss Albino Mice, is called cetylmyristoleate.
However, when the researcher reported his remarkable findings to his superiors in an attempt to secure funding for additional research, his request was mysteriously denied. Nevertheless, struggling along without authorization, he continued his studies and reported further successes. Strangely, not only were his requests for funding continuously denied, all of his accomplishments went completely unrecognized. Though they never said so directly, it was as though the NIH wanted him to abandon the project completely. Discouraged though he was, he still continued his research as best he could with absolutely no funding at all. When he retired about a decade later, since even the mere existence of his work went completely unacknowledged by the NIH, he took his discovery with him and continued the research on his own. And well he deserved to do so. Had he not, his discovery may never have come to light.
It has been reported that some time later, one by one he went to three different major pharmaceutical companies offering to share his discovery. One by one, his offers were
rejected – not for lack of effectiveness, but because the product was derived from natural sources it could not be patented in a way to hog all the profits. The companies couldn’t care less about the fact that it worked, only that they couldn’t protect it from being manufactured by some competing company. Nor did they express any interest in funding further research on the project.
One could also speculate on the likelihood that by making available a product that potentially reverses the arthritic process permanently, it would kill their annual multi-billion dollar sales of existing arthritis products – all of which must be taken repeatedly for the rest of the arthritis victims’ lives. Quite understandably, of course, the pharmaceutical companies love products that lead to a lifetime of repeat sales.
After its rejection by the pharmaceutical companies the project lay fallow for several years. No further attempts were made to explore its potential.
The chain of events that followed have never been made crystal clear. It has been reported that as some years passed, the researcher himself began to suffer terribly from arthritis and was receiving conventional medical therapy to treat it. It is important to note that despite the fact that he had explored the safety and effectiveness of his discovery on lower animals at the NIH, research had never reached the level of testing on higher animals. But once his arthritis reached excruciating extremes and his physician told him that he was beyond any effective help, the researcher decided to take a risk. He brewed up a batch of cetylmyristoleate at home and injected himself. Thus, he became the first person ever to receive the substance as a test of the discovery on human beings. We honour his courage.
It was a historic moment. He began to feel symptomatic relief the very next day, and soon he reached a point where he experienced total reversal of his arthritis. His doctor was astonished when he subsequently examined his patient and heard the whole story of the discovery.
The doctor was so impressed that he persuaded him to write an account of his research project. The doctor promised to help him get it published in the Journal of Pharmaceutical Sciences, hoping that the article might stimulate someone into continuing the exploration of the project. Then, early in 1995, a few months after the article appeared, that’s exactly what happened. The San Diego Clinic International Immunological Centre (SDC) embarked on a project to develop the discovery into a usable product.
But long before that, it seems that several years had intervened between the self-injection and the actual publication of the article. Meanwhile, it has been reported, even though the substance was provided quite informally to a couple hundred more arthritis victims with astounding success, there was no formal progress in research or development.
The journal article itself didn’t seem to stimulate much interest either. Perhaps that’s because it was only three pages long and dealt solely with mouse model studies. Besides, it was reporting on research that took place over twenty years before. Perhaps the readers thought there couldn’t be much value to something that had lain dormant so very long. Or maybe they thought there must have been more recent research that refuted the early findings. Nor did the article provoke questions about why it had been ignored by the NIH and how it came to buried for so
long – except in one instance.
*11\142\2*
Related Posts:
Leave a Reply
You must be logged in to post a comment.